Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease

Journal of Rheumatology

Volumn 39, Issue 2, 2012, Pages 276-285

  Johnson, Sindhu R ^a,b,f   Granton, John T ^c   Tomlinson, George A ^b,d   Grosbein, Haddas A ^e   Le, Thaolan ^c   Lee, Peter ^f   Seary, M Elizabeth ^e   Hawker, Gillian A ^b,g   Feldman, Brian M ^b,e  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Bayesian; Confounding; Propensity score; Pulmonary hypertension; Scleroderma; Warfarin

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN DERIVATIVE; WARFARIN;

ARTICLE; BAYES THEOREM; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; IDIOPATHIC DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCORING SYSTEM; SURVIVAL TIME; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ANTICOAGULANTS; BAYES THEOREM; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PROPORTIONAL HAZARDS MODELS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; WARFARIN;

EID: 84856541314     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110765     Document Type: Article

References (44)

1. Medsger TA Jr. Progressive systemic sclerosis. Clin Rheum Dis 1983;9:655-70.
2. Feinstein AR. Scientific standards in epidemiologic studies of the menace of daily life. Science 1988;242:1257-63. (Pubitemid 19008055)
3. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010;37:2290-8.
4. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach. Ann Rheum Dis 2003;62:1088-93. (Pubitemid 37323574)
5. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800. (Pubitemid 41798217)
6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4. (Pubitemid 46999798)
7. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
8. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:252-60.
9. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-9. (Pubitemid 47074013)
10. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
11. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-203. (Pubitemid 44883856)
12. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9. (Pubitemid 40246523)
13. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996;110:710-7. (Pubitemid 27009296)
14. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54 (1 Suppl):S78-84.
15. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545-52. (Pubitemid 44267025)
16. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: A qualitative systematic review. Eur Respir J 2006;28:999-1004. (Pubitemid 46331971)
17. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580-7. (Pubitemid 14020655)
18. Roman A, Rodes-Cabau J, Lara B, Bravo C, Monforte V, Pallissa E, et al. [Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension]. Med Clin (Barc) 2002;118:761-6.
19. Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Widlitz AC, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005;95:199-203. (Pubitemid 40092084)
20. Ogata M, Ohe M, Shirato K, Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J 1993;57:63-9. (Pubitemid 23071864)
21. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
22. Storstein O, Efskind L, Muller C, Rokseth R, Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand 1966;179:197-212.
23. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112:714-21. (Pubitemid 27410708)
24. Goodwin JF, Harrison CV, Wilcken DE. Obliterative pulmonary hypertension and thrombo-embolism. Br Med J 1963;1:701-11.
25. Goodwin JF, Harrison CV, Wilcken DE. Obliterative pulmonary hypertension and thromboembolism. Br Med J 1963;1:777-83.
26. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
27. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
28. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9. (Pubitemid 28405230)
29. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998;13:311-6. (Pubitemid 28242293)
30. Duchini A, Sessoms SL. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome. Am J Gastroenterol 1998;93:1453-6. (Pubitemid 29075181)
31. Omair MA, Johnson SR. Gastric antral vascular ectasia unmasked by alprostadil for digital ulceration in scleroderma. J Rheumatol 2011;38:784-5.
32. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001;358:1119-23. (Pubitemid 32971843)
33. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
34. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-54.
35. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol 2011;38:462-9.
36. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107.
37. Spiegelhalter D, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health care evaluation. Chichester: John Wiley and Sons Ltd.; 2004.
38. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol 2005;58:261-8. (Pubitemid 40249468)
39. Burton PR, Gurrin LC, Campbell MJ. Clinical significance not statistical significance: A simple Bayesian alternative to p values. J Epidemiol Community Health 1998;52:318-23. (Pubitemid 28230616)
40. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: The case of methotrexate in scleroderma. J Rheumatol 2009;36:323-9.
41. Chaloner K, Rhame FS. Quantifying and documenting prior beliefs in clinical trials. Stat Med 2001;581-600. (Pubitemid 32166421)
42. Bjornsson J, Edwards WD. Primary pulmonary hypertension: A histopathologic study of 80 cases. Mayo Clin Proc 1985;60:16-25. (Pubitemid 15199621)
43. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
44. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):35S-62S. (Pubitemid 38932341)